Vanguard Group Inc Bio Atla, Inc. Transaction History
Vanguard Group Inc
- $5.46 Trillion
- Q3 2024
A detailed history of Vanguard Group Inc transactions in Bio Atla, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 1,885,252 shares of BCAB stock, worth $1.17 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,885,252
Previous 1,885,252
-0.0%
Holding current value
$1.17 Million
Previous $2.58 Million
28.51%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding BCAB
# of Institutions
65Shares Held
17.4MCall Options Held
500Put Options Held
33.5K-
Israel Englander Millennium Management LLC | New York, Ny2.66MShares$1.65 Million0.0% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT2.52MShares$1.56 Million0.38% of portfolio
-
Morgan Stanley New York, NY1.86MShares$1.15 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA874KShares$541,9270.13% of portfolio
-
Black Rock Inc. New York, NY792KShares$490,7670.0% of portfolio
About BioAtla, Inc.
- Ticker BCAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,304,100
- Market Cap $22.5M
- Description
- BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...